#ESC2025 #Obesity #CardiovascularDisease #GLP1 #Semaglutide #Tirzepatide #HeartHealth Robert Gabbay MD, PhD This new STEER real-world data is quite thought-provoking
This is just another example of how the word healthy means something different to everyone, and you have to understand what your nutrition needs are in order to make the healthier choice for you, Werner said.
This helps your doctor give you the right medical advice and manage your care better
Graham further stated that since there arent currently any guidelines for stopping GLP-1 medications prior to a scan, his recommendation is to ask patients if they are taking one of these drugs and note when their last injection was
Steven Daveluy, MD, FAAD
In the US, individuals with overweight or obesity using GLP-1 RAs has increased from 21,000 in 2019 to 174,000 in 2023, which is a 700% increase in usage 11